Senexin B Inhibitor

Name: Senexin B Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5759228
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759228

Senexin B is a potent and selective inhibitor of CDK8/19(CDK8 and CDK19 with Kds of 140nM and 80nM). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Senexin B, Inhibitor

Full Product Name

Senexin B

Form/Format

Solid. Powder

Purity/Purification

99.63%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

450.55

Solubility

DMSO: 6mg/mL (13.32mM) Need ultrasonic and warming
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C27H26N6O

SMILES

CN1CCN(CC1)C(=O)c1ccc2cc(CCNc3ncnc4ccc(cc34)C#N)ccc2c1

CAS Number

1449228-40-3

Target & IC50

CDK19: ic50 80nM (Kd)
CDK8: ic50 140nM (Kd)

In Vitro

Senexin B inhibits CDK8/19 in low nanomolar range[1]

Product Categories/Family for Senexin B, inhibitor

Cell Cycle/Checkpoint; CDK

Product References and Citations for Senexin B, inhibitor

Porter D, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr PR08. doi:10.1158/1538-7445.CHTME14-PR08
Porter D, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr PR08. doi:10.1158/1538-7445.CHTME14-PR08
Chen M, Li J, Liang J, et al. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition[J]. 2019.
Chen M, Li J, Liang J, et al. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition[J]. 2019.
CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. US 9321737 B2

Other Notes

Small volumes of Senexin B, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Senexin B purchase

MBS5759228 is an inhibitor targeting Senexin B.